Tizona Therapeutics Stock

tizonatx.comBioTechFounded: 2015Funding to Date: $95.24MM

Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Tizona Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Tizona Therapeutics.

Register Today
Register for Details

For more details on financing and valuation for Tizona Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Scott Clarke
Chief Executive Officer & Board Member
Christine O'Brien
Chief Operating Officer
John Corbin Ph.D
Chief Technology Officer
Courtney Beers Ph.D
Chief Scientific Officer
Shelly Pinto
Controller & Vice President, Finance
Mark Smyth Ph.D
Advisor Board Member & Scientific Co-Founder
Joyson Karakunnel MD
Chief Medical Officer & Senior Vice President

Board Members

Daniel Hicklin Ph.D
MPM Capital
Daniel Spiegelman
Luke Evnin Ph.D
MPM Capital
Nina Kjellson
Canaan Partners
Pablo Cagnoni MD
MPM Capital
Scott Clarke
Shelley Chu Ph.D
Abingworth Management

Other companies like Tizona Therapeutics in the BioTech sector

Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.89B

News

A cancer immunotherapy teed up for clinical trials by Tizona Therapeutics is now the centerpiece of a new partnership with AbbVie, which is paying the
Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.